Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SinoMab Bioscience Ltd. ( (HK:3681) ) has shared an announcement.
SinoMab BioScience has reported positive topline data from a Phase 1 bridging study in China evaluating a new subcutaneous formulation of its lead antibody SM17 in healthy participants. The study, which compared single ascending subcutaneous doses against intravenous delivery and placebo, supports the company’s strategy to offer a more convenient route of administration for inflammatory disease patients, including those with atopic dermatitis.
The trial showed a favorable safety and tolerability profile, with no serious adverse events, no grade 3 or higher drug-related adverse events, and only one mild injection-site reaction resolving quickly. Pharmacokinetic results indicated predictable, dose-proportional exposure and robust bioavailability for the subcutaneous formulation, while immunogenicity remained low and clinically insignificant.
These findings build on earlier intravenous data in atopic dermatitis and reinforce the clinical rationale for advancing SM17’s subcutaneous version into Phase 2 trials in China. The outcome enhances SinoMab’s competitive positioning in the biologics segment for Type 2 inflammatory diseases by potentially improving patient experience and expanding treatment options through a more flexible administration route.
The most recent analyst rating on (HK:3681) stock is a Sell with a HK$1.50 price target. To see the full list of analyst forecasts on SinoMab Bioscience Ltd. stock, see the HK:3681 Stock Forecast page.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a Hong Kong–incorporated biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for inflammatory and immune-related diseases. Its pipeline includes SM17, a first-in-class humanized IgG4-k antibody targeting the interleukin-25 receptor to modulate Type 2 inflammatory responses, with atopic dermatitis among its key clinical indications in China.
Average Trading Volume: 5,235,011
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.3B
Learn more about 3681 stock on TipRanks’ Stock Analysis page.